AbbVie Inc. (ABBV) vs AstraZeneca PLC (AZN)
AZN leads on 10 of 14 compared metrics.
A side-by-side comparison of AbbVie Inc. and AstraZeneca PLC across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 13, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
Total return — ABBV vs AZN
growth of $100 · last 14yABBV +544.8%AZN +265.2%ABBV compounded faster
ABBV AZN
ABBV vs AZN: by the numbers
- •ABBV is the larger company ($402.35B vs $277.22B market cap).
- •AZN trades at the lower earnings multiple (26.92 vs 111.67 P/E).
- •AZN converts more revenue to profit (17.19% vs 5.79% net margin).
- •AZN grew revenue faster over the past five years (16.99% vs 4.59% CAGR).
- •ABBV pays the higher dividend yield (2.96% vs 1.79%).
Which is better, ABBV or AZN?
Metric tally: ABBV 4 · AZN 10It depends on what you're optimizing for:
ValueAZN(lower P/E)
GrowthAZN(faster 5Y revenue CAGR)
IncomeABBV(higher dividend yield)
Valuation
| Metric | ABBV | AZN |
|---|---|---|
| P/E ratio | 111.67 | 26.92● |
| Forward P/E | — | 15.33 |
| P/S ratio | 6.43 | 4.62● |
| P/B ratio | 14.69 | 5.90● |
| PEG ratio | — | 0.14 |
| EV / EBITDA | 27.63 | 14.92● |
| FCF yield | 5.17%● | 3.26% |
Profitability
| Metric | ABBV | AZN |
|---|---|---|
| Gross margin | 70.68% | 81.68%● |
| Operating margin | 27.60%● | 23.69% |
| Net margin | 5.79% | 17.19%● |
| ROE | 13.23% | 21.95%● |
| ROIC | 12.97% | 13.03% |
Dividends
| Metric | ABBV | AZN |
|---|---|---|
| Dividend yield | 2.96%● | 1.79% |
| Payout ratio | 284.39% | 48.48% |
Growth (annualized)
| Metric | ABBV | AZN |
|---|---|---|
| Revenue CAGR (5Y) | 4.59% | 16.99%● |
| EPS CAGR (5Y) | -2.79% | 22.02%● |
| FCF CAGR (5Y) | 3.24% | 18.52%● |
| Total return CAGR (5Y) | 18.95%● | 11.03% |
Frequently asked
- Which is better, ABBV or AZN?
- It depends on your goal. value: AZN (lower P/E); growth: AZN (faster 5Y revenue CAGR); income: ABBV (higher dividend yield). Across all compared metrics, AZN leads 10 to 4.
- Is ABBV or AZN cheaper?
- On trailing earnings, AZN is cheaper: ABBV trades at a 111.67 P/E and AZN at 26.92.
- Which has grown faster, ABBV or AZN?
- Over the past five years, AZN grew revenue faster — ABBV at a 4.59% CAGR versus AZN at 16.99%.
- Does ABBV or AZN pay a bigger dividend?
- ABBV yields 2.96% and AZN yields 1.79% based on trailing dividends and the latest price.
- Is ABBV or AZN more profitable?
- AZN runs the higher net margin — ABBV at 5.79% versus AZN at 17.19%.
- Which has been the better investment, ABBV or AZN?
- Over the past 10-year, ABBV delivered the higher annualized total return — ABBV at 18.88% versus AZN at 15.77%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
AbbVie P/E ratioAstraZeneca P/E ratioAbbVie dividend yieldAstraZeneca dividend yieldAbbVie ROEAstraZeneca ROEAbbVie operating marginAstraZeneca operating marginAbbVie revenue growthAstraZeneca revenue growthAbbVie free cash flowAstraZeneca free cash flow
AbbVie & AstraZeneca appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 13, 2026.